Trial · NCT01628848
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 Sum Score | baseline, 12 weeks after dosing | Full analysis set (FAS), last observation carried forward (LOCF) | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score (Average Score of on State and Off State) | baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | Off Time | baseline, 12 weeks after dosing | FAS subjects with measurable off time data at baseline, LOCF | Hours | MEAN |
| SECONDARY | Effective Rate in UPDRS Part 3 Sum Score | Baseline, 12 weeks after dosing | FAS, LOCF | Percentage of participants | NUMBER |
| SECONDARY | UPDRS Part 1 Sum Score | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | Effective Rate in Off Time | Baseline, 12 weeks after dosing. | FAS subjects with measurable off time data at baseline, LOCF | Percentage of participants | NUMBER |
| SECONDARY | UPDRS Part 2 Sum Score (on State) | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 2 Sum Score (Off State) | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | UPDRS Part 4 Sum Score | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and UPDRS Part 3 Sum Score | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | Total of UPDRS Part 1 Sum Score, UPDRS Part 2 Sum Score (Average Score of on State and Off State), UPDRS Part 3 Sum Score, and UPDRS Part 4 Sum Score. | Baseline, 12 weeks after dosing | FAS, LOCF | Scores on a scale | MEAN |
| SECONDARY | The Modified Hoehn & Yahr Severity of Illness | Baseline, 12 weeks after dosing | FAS, LOCF | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01628848/outcomes